CoChat
Sign Up
Cited by 132Helicobacter pylori-related gastroenterology studiesGastroesophageal reflux and treatmentsGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions

Open access
Song, Huan, Zhu, Jianwei, Lu, DongHao·2014·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd010623.pub2PMC PMC10843246
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Proton pump inhibitors (PPIs) are the most effective drugs to reduce gastric acid secretion. PPIs are one of the most commonly prescribed classes of medications worldwide. Apart from short-term application, maintenance therapy with PPIs is recommended and increasingly used in certain diseases, such as Zollinger-Ellison syndrome and gastro-oesophageal reflux disease, especially for people with erosive oesophagitis or Barrett's oesophagus. Although PPIs are generally safe, their efficacy and safety of long-term use remains unclear. The question of whether the long-term use of PPIs could promote the development of gastric pre-malignant lesions has been widely investigated, but results are inconsistent. Limited insight on this problem leads to a dilemma in decision making for long-term PPI prescription. OBJECTIVES: To compare the development or progression of gastric pre-malignant lesions, such as atrophic gastritis, intestinal metaplasia, enterochromaffin-like (ECL) cell hyperplasia, and dysplasia, in people taking long-term (six months or greater) PPI maintenance therapy. SEARCH METHODS: We searched the following databases (from inception to 6 August 2013): the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL. In addition, we searched the reference lists of included trials and contacted experts in the field. SELECTION CRITERIA: We searched for randomised controlled trials (RCTs) in adults (aged 18 years or greater) concerning the effects of long-term (six months or greater) PPI use on gastric mucosa changes, confirmed by endoscopy or biopsy sampling (or both). DATA COLLECTION AND ANALYSIS: Two review authors independently performed selection of eligible trials, assessment of trial quality, and data extraction. We calculated odds ratios (OR) for analysis of dichotomous data and mean differences for continuous data, with 95% confidence intervals (CI). MAIN RESULTS: We included seven trials (1789 participants). Four studies had high risk of bias and the risk of bias in the other three trials was unclear. In addition, it was difficult to assess possible reporting bias. We pooled 1070 participants from four RCTs to evaluate corporal atrophy development revealing an insignificantly increased OR of 1.50 (95% CI 0.59 to 3.80; P value = 0.39; low-quality evidence) for long-term PPI users relative to non-PPI users. In five eligible trials, corporal intestinal metaplasia was assessed among 1408 participants, also with uncertain results (OR 1.46; 95% CI 0.43 to 5.03; P value = 0.55; low-quality evidence). However, by pooling data of 1705 participants from six RCTs, our meta-analysis showed that participants with PPI maintenance treatment were more likely to experience either diffuse (simple) (OR 5.01; 95% CI 1.54 to 16.26; P value = 0.007; very-low-quality evidence) or linear/micronodular (focal) ECL hyperplasia (OR 3.98; 95% CI 1.31 to 12.16; P value = 0.02; low-quality evidence) than controls. No participant showed any dysplastic or neoplastic change in any included studies. AUTHORS' CONCLUSIONS: There is presently no clear evidence that the long-term use of PPIs can cause or accelerate the progression of corpus gastric atrophy or intestinal metaplasia, although results were imprecise. People with PPI maintenance treatment may have a higher possibility of experiencing either diffuse (simple) or linear/micronodular (focal) ECL cell hyperplasia. However, the clinical importance of this outcome is currently uncertain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd010623.pub2

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Genta, 2003, Effects of 6-12 months of esomeprazole treatment on the gastric mucosa, American Journal of Gastroenterology, 98, 1257, 10.1111/j.1572-0241.2003.07489.x · DOI
  2. Gardner, 1999, Evolution of Helicobacter pylori infection, gastritis and enterochromaffine-like cell hyperplasia in 443 patients with gastroesophageal reflux disease treated for one year with rabeprazole, Gastroenterology, 16, G0731
  3. Borenstein, 2008, Introduction to Meta-Analysis (Statistics in Practice)
  4. Genta, 2003, Effects of 6-12 months of esomeprazole treatment on the gastric mucosa, American Journal of Gastroenterology, 98, 1257, 10.1111/j.1572-0241.2003.07489.x · DOI
  5. Lee, 1996, Changes in the parietal cell mass after long-term therapy with high dose omeprazole in Barrett's esophagus (BE), Gastroenterology, 110, A173
  6. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2013

Cited by

Sorted by citations

See all 132

Related

See all

Metadata

Authors
Song, H., Zhu, J., & Lu, D.
Affiliations
  • Karolinska Institutet (SE)
  • Shandong University (CN)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2014-12-02
Volume
2014
Issue
12
Pages
CD010623-CD010623
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd010623.pub2
PMC
PMC10843246
OpenAlex
W1496904506
Cited by
132
References
83
Citations by year
2026: 6 · 2025: 6 · 2024: 14 · 2023: 15 · 2022: 12 · 2021: 12 · 2020: 13 · 2019: 17 · 2018: 13 · 2017: 13 · 2016: 6 · 2015: 5
FWCI
1.51
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
proton pump inhibitors, long-term PPI use, atrophic gastritis, intestinal metaplasia, enterochromaffin-like cell hyperplasia, gastric dysplasia, gastric mucosa, drug safety, maintenance therapy, erosive esophagitis, Barrett's esophagus, Zollinger-Ellison syndrome, gastroesophageal reflux disease
MeSH terms
Gastritis, Atrophic, Humans, Hyperplasia, Intestines, Metaplasia, Precancerous Conditions, Stomach Neoplasms, Time Factors, Randomized Controlled Trials as Topic, Enterochromaffin-like Cells, Proton Pump Inhibitors, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review